Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

The relationship between vitamin D, biomarkers and clinical outcome in hospitalised Covid-19 patients

Breslin et al., Proceedings of the Nutrition Society, doi:10.1017/S0029665121002214, Aug 2021
https://c19early.org/breslin.html
Progression 56% improvement lower risk ← → higher risk Vitamin D for COVID-19  Breslin et al.  SUFFICIENCY   Are vitamin D levels associated with COVID-19 outcomes? Retrospective 138 patients in Ireland Lower progression with higher vitamin D levels (p=0.026) c19early.org Breslin et al., Proceedings of the Nut.., Aug 2021 0 0.5 1 1.5 2+ RR
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 126 studies, recognized in 18 countries.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Retrospective 138 COVID-19 hospitalized patients in Ireland, showing increased risk of infiltrates on chest X-ray for patients with vitamin D deficiency, and lower vitamin D levels in patients that died (21.8 nmol/L vs. 37.8 nmol/L, p = 0.054).
This is the 90th of 226 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 115,066,047,903,039,356,928 vigintillion).
risk of progression, 55.6% lower, OR 0.44, p = 0.03, high D levels (≥30nmol/l) 106, low D levels (<30nmol/l) 32, adjusted per study, inverted to make OR<1 favor high D levels (≥30nmol/l), infiltrates on chest X-ray, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Breslin et al., 17 Aug 2021, retrospective, Ireland, peer-reviewed, 4 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Ireland United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Ireland favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Ireland United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Ireland favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
The relationship between vitamin D, biomarkers and clinical outcome in hospitalised Covid-19 patients
É Breslin, D Mccartney, C Nícheallaigh, D Byrne
Proceedings of the Nutrition Society, doi:10.1017/s0029665121002214
Previous research has identified an association between low vitamin D status and the risk and severity of acute respiratory infections 1, 2 , leading to suggestion that correction of vitamin D deficiency may improve outcome in COVID-19 patients. This study aimed to elucidate the association between low vitamin D status and adverse clinical outcomes including mortality amongst Covid-19 inpatients. Two-hundred participants were recruited from St. James Hospital, Dublin. Indices of disease severity included duration of hospitalisation, number of signs and symptoms experienced, requirement for oxygen support and ICU admission and mortality. Pearson's and Spearman's correlation tests were used to evaluate the association between serum vitamin D (25(OH)D), interleukin-6 (IL-6), D-dimer, fibrinogen and CD25 levels and disease outcome. Overall, 138 patients (69%) had measured 25(OH)D levels; 23% (n = 32) were classified as 'deficient' (25(OH)D < 30 nmol/L), 25% (n = 34) were classified as 'insufficient' (25(OH)D of 30-49.9 nmol/L) and 52% (n = 72) were classified as 'sufficient' (25(OH)D ≥ 50 nmol/l). No significant correlation was observed between circulating 25(OH)D and age. However, serum 25(OH)D was inversely associated with IL-6 (Β = -0.696, p = 0.036) and D-dimer (Β = -13.71, p = 0.002). High IL-6 levels were associated with an increased likelihood of infiltrates on chest X-ray (OR = 3.615, p = 0.044), while high D-Dimer levels were associated with an increased risk of admission to ICU (OR = 15.304, p = 0.012), and an increased likelihood of requiring oxygen support (OR = 4.035, p = 0.004). Clinically, vitamin D deficiency was associated with an increased risk of infiltrates on chest X-ray (OR = 2.253, p = 0.026). There was also a tendency towards lower vitamin D levels in patients who died (n = 15) than in those who survived (n = 123) (21.8 nmol/L vs. 37.8 nmol/L, p = 0.054). These data suggest that low vitamin D status may be associated with poorer clinical and biometric profiles and increased mortality in hospitalised Covid-19 patients. The association of low vitamin D status with higher IL-6 and higher D-dimer levels, and the association of these biometric markers with more severe clinical outcomes in this and other studies (3, 4) , suggest that these pro-inflammatory and pro-thrombotic mediators may lie at an intermediate point in the causal pathway between low vitamin D status and poorer clinical outcomes including mortality in hospitalised Covid-19 patients.
References
Baktash, Hosack, None, Postgrad Med J
Jain, Chaurasia, None
Martineau, Jolliffe, None, BMJ
Xu, Yang, None, Mol Med Rep
DOI record: { "DOI": "10.1017/s0029665121002214", "ISSN": [ "0029-6651", "1475-2719" ], "URL": "http://dx.doi.org/10.1017/S0029665121002214", "alternative-id": [ "S0029665121002214" ], "article-number": "E98", "assertion": [ { "group": { "label": "Copyright and Licensing", "name": "copyright_and_licensing" }, "label": "Copyright", "name": "copyright", "value": "Copyright © The Authors 2021" } ], "author": [ { "affiliation": [], "family": "Breslin", "given": "É.", "sequence": "first" }, { "affiliation": [], "family": "McCartney", "given": "D.", "sequence": "additional" }, { "affiliation": [], "family": "NíCheallaigh", "given": "C.", "sequence": "additional" }, { "affiliation": [], "family": "Byrne", "given": "D.", "sequence": "additional" } ], "container-title": "Proceedings of the Nutrition Society", "container-title-short": "Proc. Nutr. Soc.", "content-domain": { "crossmark-restriction": true, "domain": [ "cambridge.org" ] }, "created": { "date-parts": [ [ 2021, 8, 17 ] ], "date-time": "2021-08-17T09:18:12Z", "timestamp": 1629191892000 }, "deposited": { "date-parts": [ [ 2021, 10, 15 ] ], "date-time": "2021-10-15T15:58:20Z", "timestamp": 1634313500000 }, "indexed": { "date-parts": [ [ 2022, 11, 30 ] ], "date-time": "2022-11-30T07:28:18Z", "timestamp": 1669793298592 }, "is-referenced-by-count": 2, "issue": "OCE3", "issued": { "date-parts": [ [ 2021 ] ] }, "journal-issue": { "issue": "OCE3", "published-print": { "date-parts": [ [ 2021 ] ] } }, "language": "en", "license": [ { "URL": "https://www.cambridge.org/core/terms", "content-version": "unspecified", "delay-in-days": 228, "start": { "date-parts": [ [ 2021, 8, 17 ] ], "date-time": "2021-08-17T00:00:00Z", "timestamp": 1629158400000 } } ], "link": [ { "URL": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0029665121002214", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "56", "original-title": [], "prefix": "10.1017", "published": { "date-parts": [ [ 2021 ] ] }, "published-online": { "date-parts": [ [ 2021, 8, 17 ] ] }, "published-print": { "date-parts": [ [ 2021 ] ] }, "publisher": "Cambridge University Press (CUP)", "reference": [ { "DOI": "10.1038/s41598-020-77093-z", "doi-asserted-by": "publisher", "key": "S0029665121002214_ref3" }, { "author": "Baktash", "first-page": "26", "journal-title": "Postgrad Med J", "key": "S0029665121002214_ref4", "year": "2020" }, { "DOI": "10.3892/mmr.2017.7546", "doi-asserted-by": "publisher", "key": "S0029665121002214_ref2" }, { "DOI": "10.1136/bmj.i6583", "doi-asserted-by": "publisher", "key": "S0029665121002214_ref1" } ], "reference-count": 4, "references-count": 4, "relation": {}, "resource": { "primary": { "URL": "https://www.cambridge.org/core/product/identifier/S0029665121002214/type/journal_article" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Nutrition and Dietetics", "Medicine (miscellaneous)" ], "subtitle": [], "title": "The relationship between vitamin D, biomarkers and clinical outcome in hospitalised Covid-19 patients", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1017/policypage", "volume": "80" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit